Thursday, 15 May 2014

Ovarian Cancer - Pipeline Review, H1 2014



This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope

  • The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Ovarian Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline




Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: 
sales@marketresearchreports.biz



Uterine Cancer - Pipeline Review, H1 2014



Summary

Global Markets Directs, Uterine Cancer - Pipeline Review, H1 2014, provides an overview of the Uterine Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Cancer and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- The report provides a snapshot of the global therapeutic landscape of Uterine Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Uterine Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Uterine Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Uterine Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products


Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Uterine Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Uterine Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: 
sales@marketresearchreports.biz



Soft Tissue Sarcoma - Pipeline Review, H1 2014



This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope

  • The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline




Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: 
sales@marketresearchreports.biz



Monday, 12 May 2014

Bio-Based Propylene Glycol Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019


Propylene glycol or 1, 2-propane-diol is one of the universal product that is used in modern life and is practically everywhere. It is derived industrially by processing petroleum products and has a very high demand due to which the global consumption of petroleum has increased by thousand metric tons per year. Propylene Glycol (PG) is used in a broad range of products; it can be found in fiberglass resins, antifreezes, foods, pharmaceuticals and cosmetics.  



Propylene glycol has been prepared by petroleum stocks but now days it is derived from corn starch and a special carbohydrate which is processed to make glycols. This processed and green derived propylene glycol is having a very high quality. The synthetic ingredient is derived from a renewable source which meets the requirement of the consumers and it also offers additional advantage of a pleasant and fruity odor.  The chemical industry is highly dependent on fossil fuel for making variety of petrochemical products. As there are many benefits of renewable chemistry so the entire industry is shifting towards it, companies are demanding bio-based chemicals to achieve sustainability by commercializing bio-based chemicals. One of the elements which are in high demand and attracting attention to be generated from renewable source is propylene glycol.

The bio-based propylene glycol is in high demand due to its effective quality. These products have same area of applications as that of propylene glycol. Moreover it is a renewably derived product and helps in reducing the green house gas emissions.  These products meet the standards of bio-preferred purchasing programs and also the specifications given by the government which makes it an efficient product to be used by industries. The bio-based propylene glycol is used for all cosmetics applications and offers fruity odor and equivalent feature as that of the traditional chemical.  


The pleasant smell of bio PG is a big advantage for the industry producing perfumes and colognes and driving the demand abundantly.  Reduced green house gas emission by its production, better and benchmarked environmental performance and reduced dependency on petrochemical feedstock are some of the main drivers of this market.  The derivation of bio-based propylene glycol has a limitation of low catalyst stability and high reaction pressure during the production process which can be controlled by proper observation. There is growing demand for renewable products which gives a wide opportunity to renewable chemistry and bio-based chemicals.


The increase in demand by the industries for the bio-based products has improved energy security and reduced the dependence on imports for energy. The growing technology and advancement in biotechnology to develop industrial bio-based products have given several opportunities to this market. Moreover the growing demand for product derived from renewable raw materials has brought several opportunities for this market.

The bio based propylene glycol is used as an antifreeze, secondary refridgerant and coolant in many industries.  It is used in several applications such as waste heat recovery, chillers, HVAC and solar systems.  Bio based propylene glycol is used as anti- freeze because it has low freeze point and high boiling point, in hydraulic brake fluids, deicing fluids, paints &coatings, pharmaceuticals, cosmetics, personal care products and food.  Bio based chemicals has continues steady growth in past few years with majors markets including countries such as the U.S. and Europe.

The agribusiness has been widely producing bio-based propylene glycol using refined glycerin as the feedstock which has several applications in industries. Some of the key market players in this market include Ashland, Cargill, ADM, Dow Chemicals and BASF amongst others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


Reasons for Buying this Report
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments




Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: 
sales@marketresearchreports.biz



Muckle-Wells Syndrome Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019


Muckle-Wells Syndrome (MWS) is a rare, genetic autosomal disease which leads to urticaria, sensorineural deafness, and also leads to amyloidosis. The disease is mainly caused due to mutation of CIAS1 gene, that leads to increased production of interleukin 1B. Due to interaction of IL1B and skin receptors, the inflammation occurs, which leads to fever and rashes. The common symptoms include fevers, chills, deafness, arthritis, and recurrent urticaria.The episode of MWS usually lasts for around 48 hours. The disease belongs to a family of cryopyrin- associated periodic syndromes (CAPS), including 2 other diseases, caused by mutation of CIAS1 gene.


Muckle-Wells Syndrome can be diagnosed with the help of study of patient’s symptoms and medical evaluation. In addition, gene testing and NLRP3 mutation study also helps in diagnosis of the disease. Owing to extensive growth in genetic engineering, the market is expected to grow duringthe forecast period 2013 to 2019. The major treatments for MWS includes Rilonacept (for CAPS treatment), anakinra (IL-1 receptor antagonist) and Canakinumab, a monoclonal antibody. In addition to the existing treatments, some new treatments are under pipeline studies.

The market of Muckle-Wells Syndrome is driven by factors such as, extensive R&D activities, technological advancement in research and genetic sciences and growing concern about various genetic disorders. Extensive R&D is one of the major factor, propelling the market growth. Considering the growth perspective, many pharmaceutical and biotechnological leaders are engaged in the development of medications and treatments for this disease. However, low epidemiology, lack of awareness and high cost of R&D and treatment are some of the restraints, expected to impose a threat to the growth of the market.

Some of the major players engaged in development and commercialization of treatments for Muckle-Wells Syndrome includes Novartis AG, Istituto Giannina Gaslini, Regeneron Pharmaceuticals, Inc. and Charite-Universitatsmedizin Berlin amongst others. 


This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 



Reasons for Buying this Report
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments 



Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: 
sales@marketresearchreports.biz